These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 28612529

  • 1. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph +ALL Cell Line].
    Wu JH, Shi FF, Gong YP, Shi R.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
    [Abstract] [Full Text] [Related]

  • 2. [The Roles of Glut5 in Imatinib Resistance in the Ph+ Acute Lymphoblastic Leukemia Cell].
    Yan TY, Naren DL, Gong YP.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):389-393. PubMed ID: 28616912
    [Abstract] [Full Text] [Related]

  • 3. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
    Shi F, Yang X, Gong Y, Shi R, Yang X, Naren D, Wu J.
    Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
    [Abstract] [Full Text] [Related]

  • 4. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
    Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, Yan T.
    PLoS One; 2015 Apr; 10(8):e0136746. PubMed ID: 26317515
    [Abstract] [Full Text] [Related]

  • 5. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Teng Z, Xu S, Lei Q.
    Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
    [Abstract] [Full Text] [Related]

  • 6. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
    Seo SU, Woo SM, Lee HS, Kim SH, Min KJ, Kwon TK.
    Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
    [Abstract] [Full Text] [Related]

  • 7. [Anti-leukemia effect of oridonin on Ph(+) acute lymphoblastic leukemia cell SUP-B15].
    Guo Y, Shan QQ, Gong YP, Lin J, Yang X, Zhou RQ.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):439-43. PubMed ID: 22967375
    [Abstract] [Full Text] [Related]

  • 8. [Effects of stromal cells on sentitivity to imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
    Zhang H, Chen C, Yan Z, Song X, Chen W, Li D, Qiu T, Zhang P, Zeng L, Li Z, Xu K.
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):460-4. PubMed ID: 26134008
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Jun; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 10. [Effect of Huaier Aqueous Extract Combined with Routine Chemo-therapeutic Drugs on Human Acute Lymphoblastic Leukemia Cells Nalm-6 and Sup-B15].
    Qu P, Zhou F, Tan LF, Wang ZJ, Wang ML, Jin RM, Han J.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1451-1458. PubMed ID: 33067936
    [Abstract] [Full Text] [Related]

  • 11. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
    Yang X, He G, Gong Y, Zheng B, Shi F, Shi R, Yang X.
    Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
    [Abstract] [Full Text] [Related]

  • 12. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y, Chen X, Luo Z.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [Abstract] [Full Text] [Related]

  • 13. Core Target and Key Signal Pathway of Xiaoluo in the Treatment of Thyroid Cancer.
    Liang W, Zhang K, Sun Y, Chen L, Wang Z, Cheng W, Li W.
    Altern Ther Health Med; 2023 Jul; 29(5):400-409. PubMed ID: 37171951
    [Abstract] [Full Text] [Related]

  • 14. The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.
    Xing H, Yang X, Liu T, Lin J, Chen X, Gong Y.
    Leuk Res; 2012 Apr; 36(4):509-13. PubMed ID: 22285507
    [Abstract] [Full Text] [Related]

  • 15. [Effect of VE-cadherin on sensitivity to Imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells].
    Zhang HX, Yan ZL, Song XG, Lü C, Cao J, Li ZY, Zeng LY, Chen C, Xu KL.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):522-6. PubMed ID: 23827112
    [Abstract] [Full Text] [Related]

  • 16. [Multidrug resistant gene MDR1 contributes to development of imatinib-resistance in Ph (+) acute lymphoblastic leukemia cell line SUP-BS15RI].
    Lin J, Xing HY, Gong YP, Yang X, Guo Y, Shan QQ, Zhou RQ.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 43(5):657-60, 665. PubMed ID: 23230732
    [Abstract] [Full Text] [Related]

  • 17. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [Abstract] [Full Text] [Related]

  • 18. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
    Deng M, Wang J, Chen Y, Zhang L, Liu D.
    Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
    [Abstract] [Full Text] [Related]

  • 19. Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
    Naren D, Wu J, Gong Y, Yan T, Wang K, Xu W, Yang X, Shi F, Shi R.
    Leuk Res; 2016 Mar; 42():59-67. PubMed ID: 26818574
    [Abstract] [Full Text] [Related]

  • 20. Huaier extract enhances the treatment efficacy of imatinib in Ik6+ Ph+ acute lymphoblastic leukemia.
    Qu P, Han J, Qiu Y, Yu H, Hao J, Jin R, Zhou F.
    Biomed Pharmacother; 2019 Sep; 117():109071. PubMed ID: 31202171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.